The Immune-Mediated Inflammatory Disease Forum
The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Author
The Immune-Mediated Inflammatory Disease Forum
Category
Podcast website
Latest episode
Jul 9, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab 11.12.2025 13:08
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA 04.12.2025 20:47
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA 27.11.2025 9:45
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The se...
Author Interview: Professor Filip Rob, 2025 20.11.2025 25:07
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younge...
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2 16.11.2025 17:02
Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis 13.11.2025 14:37
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab 06.11.2025 5:15
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.
ACR 2025 Review Podcast 05.11.2025 40:15
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
ACR Daily Highlights Day 4 29.10.2025 1:48
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)
ACR Daily Highlights: Day 3 28.10.2025 3:49
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)
Pathways Modulating IMIDs: Webinar Highlights Podcast 28.10.2025 24:49
Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.
ACR Daily Highlights: Day 2 27.10.2025 4:03
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)
ACR Daily Highlights: Day 1 26.10.2025 3:49
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)
ACR 2025 Preview Podcast 22.10.2025 22:47
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies 09.10.2025 18:31
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Author Interview: Doctor David Kellner, September 2025 02.10.2025 22:44
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.
Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases 25.09.2025 8:44
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA 18.09.2025 20:52
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis 04.09.2025 7:41
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025 28.08.2025 28:57
Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025 14.08.2025 45:23
Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheuma...
Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials 07.08.2025 17:45
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.
Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting 31.07.2025 13:24
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA 10.07.2025 16:44
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.
Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash 03.07.2025 41:27
Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.